Format

Send to

Choose Destination
Int J Mol Sci. 2019 Apr 12;20(8). pii: E1822. doi: 10.3390/ijms20081822.

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.

Author information

1
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. chudinhtoi.hnue@gmail.com.
2
School of Odonto Stomatology, Hanoi Medical University, Hanoi 100000, Vietnam. chudinhtoi.hnue@gmail.com.
3
Institute of Cancer Research, Oslo University Hospital, 0372 Oslo, Norway. chudinhtoi.hnue@gmail.com.
4
Department of Education and Training, Vietnam Military Medical University, Hanoi 100000, Vietnam. bac_hvqy@yahoo.com.
5
National Food Institute, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. hoangtc@gmail.com.
6
Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi 100000, Vietnam. bstiencsvd@gmail.com.
7
Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi 100000, Vietnam. thanhvo@hmu.edu.vn.
8
Institute for Research and Development, Duy Tan University, 03 Quang Trung, Danang 550000, Vietnam. vunguyenphuong.n@gmail.com.
9
School of Odonto Stomatology, Hanoi Medical University, Hanoi 100000, Vietnam. votruongnhungoc@gmail.com.
10
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. daodangduc@gmail.com.
11
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. lengochoan@gmail.com.
12
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. hungnp@hnue.edu.vn.
13
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. trungthuhnue@gmail.com.
14
AI Lab, Faculty of Information Technology, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam. phamvanhuy@tdtu.edu.vn.
15
Organ Transplantation Center, Viet Duc Hospital, Hanoi 100000, Vietnam. nguyenvu.urologue@gmail.com.
16
Faculty of Odonto-Stomatology, University of Medicine and Pharmacy, Ho Chi Minh City 700000, Vietnam. pavthuy@ump.edu.vn.
17
Institute of Cancer Research, Oslo University Hospital, 0372 Oslo, Norway. deepak.balaji@bitsaa.org.

Abstract

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.

KEYWORDS:

CD137/4-1BB; CD137L/4-1BBL; anti-CD137 antibodies; anti-CD137 antibody therapy; cancer immunotherapies

PMID:
31013788
DOI:
10.3390/ijms20081822
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for Norwegian BIBSYS system
Loading ...
Support Center